Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Piperidine
Me gusta
Guardar
Compartir
Me gusta
Guardar
Compartir
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases | Synapse